Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report)’s stock price reached a new 52-week high on Tuesday . The company traded as high as $715.99 and last traded at $706.73, with a volume of 262519 shares changing hands. The stock had previously closed at $683.41.
Wall Street Analyst Weigh In
AXON has been the subject of a number of recent analyst reports. Northland Securities upped their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. JMP Securities upped their target price on Axon Enterprise from $610.00 to $725.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 4th. Robert W. Baird upped their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. TD Cowen started coverage on Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. Finally, Needham & Company LLC upped their price objective on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $542.15.
View Our Latest Report on AXON
Axon Enterprise Trading Up 3.9 %
Insider Buying and Selling
In other Axon Enterprise news, insider Jeffrey C. Kunins sold 1,035 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $624.47, for a total value of $646,326.45. Following the transaction, the insider now owns 124,243 shares in the company, valued at approximately $77,586,026.21. This represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the transaction, the director now owns 6,929 shares in the company, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,711 shares of company stock valued at $5,631,561 over the last 90 days. Company insiders own 6.10% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock worth $5,019,886,000 after acquiring an additional 275,959 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Axon Enterprise by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock valued at $1,095,542,000 after purchasing an additional 65,097 shares in the last quarter. Capital World Investors lifted its holdings in shares of Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Axon Enterprise by 12.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after purchasing an additional 127,769 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock valued at $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
- Five stocks we like better than Axon Enterprise
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What Is WallStreetBets and What Stocks Are They Targeting?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.